DE69809222D1 - DEVICES FOR INTRAVAGINAL ADMINISTRATION OF TESTOSTERONE AND TESTOSTERONE PRECONDITIONAL COMPOUNDS - Google Patents

DEVICES FOR INTRAVAGINAL ADMINISTRATION OF TESTOSTERONE AND TESTOSTERONE PRECONDITIONAL COMPOUNDS

Info

Publication number
DE69809222D1
DE69809222D1 DE69809222T DE69809222T DE69809222D1 DE 69809222 D1 DE69809222 D1 DE 69809222D1 DE 69809222 T DE69809222 T DE 69809222T DE 69809222 T DE69809222 T DE 69809222T DE 69809222 D1 DE69809222 D1 DE 69809222D1
Authority
DE
Germany
Prior art keywords
testosterone
preconditional
compounds
devices
intravaginal administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69809222T
Other languages
German (de)
Other versions
DE69809222T2 (en
Inventor
Clare Passmore
Claire Gilligan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Chilcott Ireland Ltd
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Application granted granted Critical
Publication of DE69809222D1 publication Critical patent/DE69809222D1/en
Publication of DE69809222T2 publication Critical patent/DE69809222T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Abstract

This invention relates to an intravaginal shell or core drug delivery device suitable for administration to female humans or animals comprises testosterone or a testosterone precursor in a polymer matrix, surrounded by a sheath, and is capable of releasing the testosterone or testosterone precursor in a substantially zero-order pattern on a daily basis for at least three weeks. The device is intended to restore circulating testosterone levels to the normal physiol, range or to induce supratherapeutic testosterone levels.
DE69809222T 1997-05-07 1998-05-07 DEVICES FOR INTRAVAGINAL ADMINISTRATION OF TESTOSTERONE AND TESTOSTERONE PRECONDITIONAL COMPOUNDS Expired - Lifetime DE69809222T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (2)

Publication Number Publication Date
DE69809222D1 true DE69809222D1 (en) 2002-12-12
DE69809222T2 DE69809222T2 (en) 2003-08-14

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69809222T Expired - Lifetime DE69809222T2 (en) 1997-05-07 1998-05-07 DEVICES FOR INTRAVAGINAL ADMINISTRATION OF TESTOSTERONE AND TESTOSTERONE PRECONDITIONAL COMPOUNDS

Country Status (15)

Country Link
US (1) US6416780B1 (en)
EP (1) EP0981327B1 (en)
JP (1) JP2001524124A (en)
CN (1) CN1184957C (en)
AT (1) ATE227120T1 (en)
AU (1) AU741482B2 (en)
CA (1) CA2288046C (en)
DE (1) DE69809222T2 (en)
DK (1) DK0981327T3 (en)
ES (1) ES2187024T3 (en)
IL (1) IL132702A0 (en)
NO (1) NO995419L (en)
NZ (1) NZ501236A (en)
PT (1) PT981327E (en)
WO (1) WO1998050016A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US9993424B2 (en) 2002-03-27 2018-06-12 Allergan Pharmaceuticals International Limited Intravaginal matrix drug delivery devices
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
EP2377569A1 (en) 2004-07-02 2011-10-19 QLT Plug Delivery, Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
DK1933810T3 (en) 2005-08-11 2013-01-28 Childrens Medical Center Intravesical drug delivery device and method
CN103393483B (en) 2006-03-31 2016-08-24 玛提治疗有限公司 Medicine release method, structure and composition for nose tear system
AU2007319580B2 (en) 2006-10-12 2012-11-29 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0820800B8 (en) 2007-12-11 2021-06-22 Massachusetts Inst Technology implantable medical device for controlled drug release
SI2249757T1 (en) * 2008-02-04 2017-10-30 Ferring B.V. Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
CN102176931B (en) 2008-08-09 2015-03-04 麻省理工学院 Implantable drug delivery device and methods of treating male genitourinary and surrounding tissues
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN103664973B (en) 2008-10-17 2017-04-19 泽农医药公司 Spiro-oxindole compounds and their use as therapeutic agents
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
EA023156B1 (en) 2009-06-26 2016-04-29 ТАРИС Биомедикал ЛЛК Drug delivery device
AR077252A1 (en) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
MY179342A (en) 2009-10-14 2020-11-04 Xenon Pharmaceuticals Inc Synthetic methods for spiro-oxindole compounds
EP3266444A1 (en) 2010-02-26 2018-01-10 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
JP2014503554A (en) 2011-01-10 2014-02-13 タリス バイオメディカル，インコーポレイテッド Lidocaine regimen for the use of continuous treatment of bladder pain and irritating urination
CA2825399A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
DK3290024T3 (en) 2011-08-29 2019-06-03 Mati Therapeutics Inc CONTINUING SUBMISSION OF ACTIVE RESOURCES FOR TREATMENT OF GLAUCUM AND OCULAR HYPERTENSION
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
CA2853439A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
JP2016514459A (en) 2013-03-15 2016-05-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア A dual-reactive potent Kunitz inhibitor for fibrinolysis
KR102385603B1 (en) 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 Multi-unit drug delivery devices and methods
CN104546668B (en) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 Liquid silastic is the preparation and application of the medicine sustained and controlled release system of carrier
CN105392454B (en) * 2014-06-28 2018-05-08 安德罗玛克实验室股份有限公司 For preventing the cerclage pessary containing extension, constant and sustained release progesterone of premature labor
TW201636017A (en) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
US10758530B2 (en) 2016-02-19 2020-09-01 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
KR102366077B1 (en) 2016-05-20 2022-02-21 제논 파마슈티칼스 인크. Benzenesulfonamide compounds and their use as therapeutic agents
RU2760303C2 (en) 2016-12-09 2021-11-23 Ксенон Фармасьютикалз Инк. Benzenesulfonamide compounds and their use as therapeutic agents
IL278949B1 (en) 2018-06-13 2024-04-01 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
KR20210061332A (en) 2018-07-27 2021-05-27 제논 파마슈티칼스 인크. How to treat epilepsy
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
BR112021000209A2 (en) 2018-08-31 2021-08-24 Xenon Pharmaceuticals Inc. Heteroaryl Substituted Sulphonamide Compounds and Their Use as Therapeutic Agents
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
EP3924352A4 (en) 2019-02-11 2022-11-16 Phoenix Molecular Designs Crystalline forms of an rsk inhibitor
WO2023049369A2 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridinyl derivatives as sodium channel activators
AU2022349462A1 (en) 2021-09-24 2024-04-11 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
TW202328091A (en) 2021-09-24 2023-07-16 加拿大商再諾製藥公司 Pyridinylacetamide derivatives as sodium channel activators
WO2023239729A1 (en) 2022-06-08 2023-12-14 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
AU538961B2 (en) * 1980-06-09 1984-09-06 Alex Harvey Industries Limited Intra-vaginal device
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
CN1255056A (en) 2000-05-31
CA2288046C (en) 2006-10-03
WO1998050016A3 (en) 1999-02-04
CA2288046A1 (en) 1998-11-12
WO1998050016A2 (en) 1998-11-12
NZ501236A (en) 2002-02-01
JP2001524124A (en) 2001-11-27
EP0981327A2 (en) 2000-03-01
IL132702A0 (en) 2001-03-19
DE69809222T2 (en) 2003-08-14
ATE227120T1 (en) 2002-11-15
NO995419D0 (en) 1999-11-05
AU7446998A (en) 1998-11-27
NO995419L (en) 2000-01-07
PT981327E (en) 2003-02-28
US6416780B1 (en) 2002-07-09
AU741482B2 (en) 2001-11-29
DK0981327T3 (en) 2003-03-10
EP0981327B1 (en) 2002-11-06
ES2187024T3 (en) 2003-05-16
CN1184957C (en) 2005-01-19

Similar Documents

Publication Publication Date Title
DE69809222T2 (en) DEVICES FOR INTRAVAGINAL ADMINISTRATION OF TESTOSTERONE AND TESTOSTERONE PRECONDITIONAL COMPOUNDS
WO2003077972A8 (en) Implantable drug delivery system
AU1227899A (en) Osmotic medicament releasing system
ID21259A (en) DRUG DISTRIBUTION SYSTEMS FOR TWO OR MORE ACTIVE INGREDIENTS
CA2298245A1 (en) Matrix controlled release device
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
ES2192226T3 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING ANTIMICROBIAL ACTIVE AGENTS AND PROLONGED LIBERATION PANTOPRAZOL.
EP1504758A3 (en) Controlled-release formulations coated with aqueous dispersions of ethylcellulose
PT1238660E (en) SUSTAINED DISTRIBUTION OF AN ACTIVE AGENT USING AN IMPLANTABLE SYSTEM
BR0014929A (en) Drug delivery device, and process for delivering a pharmaceutically active agent to a target tissue within a body
AU3990797A (en) Sustained release formulation
PT1017391E (en) FORMULATION OF PROLONGED LIBERATION TABLETS FOR TREATING PARKINSON'S DISEASE
FR2774288B1 (en) GASTROPROTEGED OMEPRAZOLE MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
SI1017392T1 (en) Medicament formulation with a controlled release of an active agent
IL113053A (en) Targeted or sustained release pharmaceutical forms of alfuzosin hydrochloride
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
MY129726A (en) Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics
EP1106609A3 (en) Aminoalcohol derivative and medicament comprising the same
NZ309697A (en) Novel formulation for peptide release
ATE236621T1 (en) LOW DOSE TABLETS AND METHOD FOR THEIR PRODUCTION
ZA9711660B (en) Therapeutic agent and treatment for canine intractable dermatitis.
PT8662T (en) DETERMINANT FOR DISTRIBUTING AN INOPHROR MEDICINE APPLIED IN SPECIAL FOR ANIMAL TREATMENT
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases
MX9605633A (en) Pharmaceutical composition for preventing or treating dry eye or disease caused therefrom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition